Dr. Yu received his undergraduate degree in chemistry from Fudan University in 2001. He received his Ph.D. in Chemistry from the University of California, Berkeley in 2006 under the direction of Julie Leary, where he developed mass spectrometric approaches for the study of protein-ligand interactions. As a graduate student, he also developed a series of proteomic technologies for the study of tyrosine sulfation, a protein post-translational modification that is implicated in regulating protein-protein interactions in the extracellular space.
In 2007, Dr. Yu joined the laboratories of Steven Gygi and John Blenis in the Department of Cell Biology at Harvard Medical School for his post-doctoral training (in both quantitative proteomics and signal transduction). There he developed quantitative mass spectrometric strategies for the study of protein phosphorylation. He deployed these powerful technologies to characterize the PI3K/Akt/mTORC1 pathway, and identified their downstream signaling modules that control a variety of cellular anabolic processes.
In 2012, Dr. Yu began his independent research career as an Assistant Professor in the Department of Biochemistry at UT Southwestern Medical Center. He was promoted to Associate Professor with tenure in 2017. Throughout his career, Dr. Yu has been the recipient of numerous awards for his research, including the Tuberous Sclerosis Alliance Postdoctoral Fellowship, a CPRIT Scholar in Cancer Research award, a Virginia Murchison Linthicum Scholar in Medical Research award, a Research Scholar award from the American Cancer Society, a UT System Rising STARs Award and most recently, an R35 MIRA award from NIGMS. He has served on many NIH and DoD advisory panels, including as a current member of the NIH Enabling Bioanalytical and Imaging Technologies (EBIT) Study Section.
The long-term goals of the Yu lab are to develop cutting-edge, mass spectrometry-based proteomic technologies, and applying them to systematically identify novel protein modifications and the related "dark matter" within in the human proteome. These data-driven strategies are then combined with classical biochemistry approaches to chacterize aberrant protein modification patterns, decipher the mechanisms of their deregulation, establish the functional consequences of these molecular events, facilitate the development of relevant therapeutic strategies, and finally, identify proteomic signatures that may serve as diagnostic, prognostic or predictive biomarkers for the relevant diseases (e.g., cancer, diabetes and neurodegenerative disease).
- Fudan University (2001), Chemistry
- Graduate School
- Univ of California-Berkeley (2006), Chemistry
- Mass Spectrometry
- Post-translational Modifications (e.g. Phosphorylation and ADP-ribosylation)
- Quantitative Proteomics
- Signal Transduction/Cancer Biology and Metabolism
- Determination of the sites of tyrosine O-sulfation in peptides and proteins.
- Yu Y, Hoffhines AJ, Moore KL, Leary JA Nat. Methods 2007 Jul 4 7 583-8
- A Proteomic Connectivity Map for Characterizing the Tumor Adaptive Response to Small Molecule Chemical Perturbagens.
- Zi Z, Zhang Y, Zhang P, Ding Q, Chu M, Chen Y, Minna JD, Yu Y, ACS Chem. Biol. 2019 Dec
- Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling.
- Li N, Wang Y, Neri S, Zhen Y, Fong LWR, Qiao Y, Li X, Chen Z, Stephan C, Deng W, Ye R, Jiang W, Zhang S, Yu Y, Hung MC, Chen J, Lin SH, Nat Commun 2019 Sep 10 1 4363
- Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis.
- Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, Zhao XY, Ji Y, Li C, Guo L, Zhou L, Chen Z, Leon-Mimila P, Chung MT, Kurabayashi K, Opp J, Campos-Pérez F, Villamil-Ramírez H, Canizales-Quinteros S, Lyons R, Lumeng CN, Zhou B, Qi L, Huertas-Vazquez A, Lusis AJ, Xu XZS, Li S, Yu Y, Li JZ, Lin JD, Mol. Cell 2019 Aug 75 3 644-660.e5
- Demethylation of the Protein Phosphatase PP2A Promotes Demethylation of Histones to Enable Their Function as a Methyl Group Sink.
- Ye C, Sutter BM, Wang Y, Kuang Z, Zhao X, Yu Y, Tu BP Mol. Cell 2019 Feb
- Site-specific analysis of the Asp- and Glu-ADP-ribosylated proteome by quantitative mass spectrometry.
- Li P, Zhen Y, Yu Y, Meth. Enzymol. 2019 626 301-321
- Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi.
- Xiong X, Wang Q, Wang S, Zhang J, Liu T, Guo L, Yu Y, Lin JD Mol Metab 2018 Dec
- Quantitative phosphoproteomic analysis of the molecular substrates of sleep need.
- Wang Z, Ma J, Miyoshi C, Li Y, Sato M, Ogawa Y, Lou T, Ma C, Gao X, Lee C, Fujiyama T, Yang X, Zhou S, Hotta-Hirashima N, Klewe-Nebenius D, Ikkyu A, Kakizaki M, Kanno S, Cao L, Takahashi S, Peng J, Yu Y, Funato H, Yanagisawa M, Liu Q Nature 2018 Jun
- Loss of a Negative Regulator of mTORC1 Induces Aerobic Glycolysis and Altered Fiber Composition in Skeletal Muscle.
- Dutchak PA, Estill-Terpack SJ, Plec AA, Zhao X, Yang C, Chen J, Ko B, Deberardinis RJ, Yu Y, Tu BP Cell Rep 2018 May 23 7 1907-1914
- mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-Dependent Foxk1 Phosphorylation.
- He L, Gomes AP, Wang X, Yoon SO, Lee G, Nagiec MJ, Cho S, Chavez A, Islam T, Yu Y, Asara JM, Kim BY, Blenis J Mol. Cell 2018 May
Honors & Awards
- R35 MIRA award
- Special issue of Future of Biochemistry
- Developmental Research Program Award
NCI Lung Cancer SPORE (Specialized Programs of Research Excellence) (2017)
- Young Investigator Award
Chinese American Diabetes Association (2017)
- ACS Research Scholar
American Cancer Society (2015)
- CPRIT Scholar in Cancer Research
Cancer Prevention Research Institute of Texas (2011)
- University of Texas STARS award
University of Texas System (2011)
- Virginia Murchison Linthicum Scholar in Medical Research
UT Southwestern Medical Center (2011)
- Tuberous Sclerosis Alliance Postdoctoral Fellowship
Tuberous Sclerosis Alliance (2008)
- Chun-Tsung Scholar
Chun-Tsung Endowment (1999)
- American Association for Cancer Research (2013)
- American Society for Mass Spectrometry (2001)